A drug made by Boehringer Ingelheim and Zealand Pharma helped people lose 16.6% of their body weight in a late-stage trial (a big test before the FDA decides whether to approve a medicine). This is positive news for the companies' weight-loss drug program.

• •Boehringer-Zealand drug delivered 16.6% weight loss in late-stage trial
• •Trial is Phase 3 (pre-FDA decision stage)

Boehringer Ingelheim's survodutide, a dual-action drug that targets two hormones (glucagon and GLP-1) to help with weight loss, showed people lost an average of 16.6% of their body weight in a late-stage trial. The drug also improved other measures of metabolic health in people with obesity or excess weight.

• •Survodutide delivered 16.6% weight loss in Phase 3 obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim, partnered with Zealand
• •Trial showed metabolic improvements in people with obesity or overweight

Boehringer Ingelheim and Zealand Pharma's obesity drug showed results in a Phase 3 trial (a late-stage test) that resembled Novo Nordisk's Wegovy (a popular weight-loss medicine). The comparison suggests the drug may be competitive in the weight-loss market.

• •Boehringer/Zealand obesity drug posted Phase 3 results compared to Novo's Wegovy
• •Trial profile described as 'more akin' to Wegovy